The Brand Name INNOTOP ES Has Generic Salt :: Esomeprazole
INNOTOP ES Is From Company INNOVA LIFESCI. Priced :: Rs. 59.5
INNOTOP ES have Esomeprazole is comes under Sub class GERD, of Main Class Gastrointestinal System
Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: GERD,
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.
Drug Dose ::
Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day. Peptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk. Zollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day. Gastro-oesophageal reflux disease: 20 mg once daily for 4 wk. The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered. Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating.
Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
Drug Precautions ::
Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.
Drug Side Effects ::
The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.
Pregnancy category ::
Drug Mode of Action ::
Esomeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase in the gastric parietal cell. It is the S-isomer of omeprazole.
Drug Interactions ::
Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts. Potentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.